Lorbriqua 25mg Tablet
Marketer
Pfizer Ltd
Salt Composition
Lorlatinib (25mg)
Overview Lorbriqua 25mg Tablet
Brivanib 25mg tablets are indicated for adults with advanced, recurrent, or surgically inaccessible non-small cell lung cancer (NSCLC). Its mechanism involves anaplastic lymphoma kinase (ALK) enzyme inhibition, specifically in patients exhibiting ALK enzyme abnormalities. This medication is reserved for patients exhibiting resistance to prior ALK inhibitors like alectinib or ceritinib. Importantly, Brivanib 25mg is also effective against ALK-positive NSCLC with brain metastases. Administer with or without food, consistently at the same time daily. Dosage adjustments or temporary treatment interruptions may occur based on individual response and clinical status. Continue as prescribed; abrupt cessation is discouraged. Common adverse reactions include peripheral edema (swelling in extremities), peripheral neuropathy (numbness and tingling in limbs), and cognitive impairment (confusion, memory lapses, reduced concentration). Additional potential side effects encompass dyspnea, asthenia, weight increase, arthralgia, mood alterations, and diarrhea. Report concerning or escalating side effects to your physician for potential dosage modification or management strategies. Prior to commencing treatment, disclose any pre-existing medical conditions, including renal or cardiac disease, depression, seizures, arrhythmias, respiratory disorders, hypertension, hyperlipidemia, and diabetes. Pregnant or lactating individuals should seek medical counsel before initiating therapy. Inform your physician of all concurrent medications, as drug interactions may occur.
Uses of Lorbriqua 25mg Tablet
Managing Non-small Cell Lung Carcinoma
Major Benefits of Lorbriqua 25mg Tablet:
Consume this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Lorbriqua 25mg Tablet can be administered with or without food, though consistent timing is recommended.
Common Side effects of Lorbriqua 25mg Tablet:
- Fatigue
- Diarrhea
- Edema (swelling)
- High blood pressure
- Cough
- Joint pain
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Weight gain
- Breathlessness
- Mood changes
- Hypercholesterolemia (high cholesterol)
- Increased triglyceride level in blood
How to use Lorbriqua 25mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Lorbriqua 25mg Tablets can be administered with or without food, though consistent timing is recommended.
How Lorbriqua 25mg Tablet works:
Oncaspar 25mg tablets are an antineoplastic agent. Their mechanism of action involves inhibiting the activity of a faulty protein responsible for stimulating cancerous cell proliferation, thereby hindering or retarding tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Lorbriqua 25mg Tablets may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Lorbriqua 25mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the potential benefits against any risks before prescribing. Always seek medical advice.
Breast feedingCAUTION
The use of Lorbriqua 25mg tablets necessitates prudence while breastfeeding. Mothers should discontinue breastfeeding for the duration of their treatment and until the medication is fully cleared from their system.
DrivingCONSULT YOUR DOCTOR
The effect of Lorbriqua 25mg Tablet on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneyCAUTION
Patients with severe kidney disease should use Lorbriqua 25mg Tablets cautiously, potentially requiring a modified dosage. Consult your physician for guidance. Dosage alteration isn't necessary for individuals with mild or moderate kidney impairment.
LiverSAFE IF PRESCRIBED
Lorbriqua 25mg tablets are considered safe for individuals with liver disease, and no dosage modification is advised. Nevertheless, a defined dosing schedule for patients experiencing moderate to severe hepatic dysfunction remains undetermined.
What if you forget to take Lorbriqua 25mg Tablet :
NA
Facts to Know About Lorbriqua 25mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Phenylpropanoids |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Kinase inhibitors targeting tyrosine |
3,018 People bought this recently